BR112012003834A2 - métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote - Google Patents

métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote

Info

Publication number
BR112012003834A2
BR112012003834A2 BR112012003834A BR112012003834A BR112012003834A2 BR 112012003834 A2 BR112012003834 A2 BR 112012003834A2 BR 112012003834 A BR112012003834 A BR 112012003834A BR 112012003834 A BR112012003834 A BR 112012003834A BR 112012003834 A2 BR112012003834 A2 BR 112012003834A2
Authority
BR
Brazil
Prior art keywords
treating
hypertriglyceridemia
hypercholesterolemia
package
methods
Prior art date
Application number
BR112012003834A
Other languages
English (en)
Inventor
Kroon Henk-Andre
Henry William
Original Assignee
Targeted Delivery Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Delivery Tech Limited filed Critical Targeted Delivery Tech Limited
Publication of BR112012003834A2 publication Critical patent/BR112012003834A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
BR112012003834A 2009-08-21 2010-08-20 métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote BR112012003834A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23599209P 2009-08-21 2009-08-21
US31447610P 2010-03-16 2010-03-16
US32015410P 2010-04-01 2010-04-01
PCT/US2010/046245 WO2011022707A1 (en) 2009-08-21 2010-08-20 Vesicular formulations

Publications (1)

Publication Number Publication Date
BR112012003834A2 true BR112012003834A2 (pt) 2017-08-08

Family

ID=43607355

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012003834A BR112012003834A2 (pt) 2009-08-21 2010-08-20 métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote

Country Status (18)

Country Link
US (3) US20120232034A1 (pt)
EP (1) EP2467170A4 (pt)
JP (2) JP2013502436A (pt)
KR (1) KR20120129864A (pt)
CN (1) CN102770162B (pt)
AU (1) AU2010283998B2 (pt)
BR (1) BR112012003834A2 (pt)
CA (1) CA2774891A1 (pt)
CL (1) CL2012000446A1 (pt)
CO (1) CO6511256A2 (pt)
DE (1) DE112010003355T5 (pt)
EA (1) EA201290108A1 (pt)
GB (1) GB2486371A (pt)
IL (1) IL218231A0 (pt)
MX (1) MX336482B (pt)
NZ (1) NZ598906A (pt)
SG (1) SG178502A1 (pt)
WO (1) WO2011022707A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012003834A2 (pt) 2009-08-21 2017-08-08 Targeted Delivery Tech Limited métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote
WO2012126965A1 (en) * 2011-03-21 2012-09-27 Gregor Cevc Drug-free compositions and methods for diminishing peripheral inflammation and pain
KR101353443B1 (ko) * 2012-02-07 2014-01-29 주식회사 아미팜 데옥시콜린산 나트륨이 없는 포스파티딜콜린 함유 주사제 조성물 및 이의 제조방법
GB201205642D0 (en) * 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201206486D0 (en) * 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
GB201208409D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
US20160193147A1 (en) * 2013-07-31 2016-07-07 Sequessome Technology Holdings Limited Vesicles
KR102296259B1 (ko) 2013-10-25 2021-08-30 인스메드 인코포레이티드 프로스타사이클린 화합물, 조성물 및 이의 사용 방법
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
EP3904326A1 (en) 2014-11-18 2021-11-03 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
CA3026466A1 (en) 2015-06-30 2017-01-05 Sequessome Technology Holdings Limited Blended formulations
KR101743960B1 (ko) * 2015-07-06 2017-06-08 서울대학교산학협력단 G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
JP6755530B2 (ja) * 2016-09-02 2020-09-16 国立大学法人岩手大学 皮膚炎の予防又は治療用医薬組成物
KR20220002600A (ko) 2019-04-29 2022-01-06 인스메드 인코포레이티드 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법
US20230372315A1 (en) * 2020-09-29 2023-11-23 Ishihara Sangyo Kaisha, Ltd. Liquid-State Pharmaceutical Composition Exhibiting Excellent Preservative Effectiveness

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60136511A (ja) * 1983-12-26 1985-07-20 Eisai Co Ltd 高尿酸血症治療剤
JPS63501289A (ja) 1985-09-27 1988-05-19 ザ　リ−ジエンツ　オブ　ザ　ユニバ−シテイ　オブ　カリフオルニア リポソ−ム経皮薬剤供給系
JPS6295134A (ja) 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5498607A (en) * 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
WO1992003122A1 (de) 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
DE59307395D1 (de) 1992-07-08 1997-10-23 Dianorm G Maierhofer Gmbh Liposomen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung eines arzneimittels
FR2714382B1 (fr) * 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
FR2767691B1 (fr) 1997-08-27 2000-02-18 Oreal Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire
BR9814214B1 (pt) 1997-11-19 2010-07-13 composição com ácido azeláico.
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
EP1107729A1 (en) 1998-09-01 2001-06-20 Idea Ag Electrically controlled transport of charged penetrants across barriers
RU2207844C2 (ru) 1998-12-23 2003-07-10 Идеа Аг. УСОВЕРШЕНСТВОВАННЫЙ ПРЕПАРАТ ДЛЯ МЕСТНОГО НЕИНВАЗИВНОГО ПРИМЕНЕНИЯ in vivo
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US6248728B1 (en) * 2000-03-10 2001-06-19 Kansas State University Research Foundation Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
US6191121B1 (en) 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
ATE382333T1 (de) 2000-04-12 2008-01-15 Liplasome Pharma As Auf lipiden basierende arzneistoffabgabesysteme gegen parasitäre infektionen
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
WO2002062316A1 (de) 2001-02-08 2002-08-15 Vectron Therapeutics Ag Invasomen zur therapie von erkrankungen, ihre herstellung und verwendung
EP1406571A4 (en) 2001-06-25 2007-05-30 Depuy Int Ltd LIPOSOMAL ENCAPSULATION OF GLYCOSAMINOGLYCANS FOR THE TREATMENT OF ARTHROSIS JOINTS
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
CA2476859C (en) 2002-03-13 2011-09-20 Collagenex Pharmaceuticals, Inc. Water-based delivery systems
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
BR0315148A (pt) 2002-10-11 2005-08-16 Idea Ag Agregado com deformabilidade aumentada, compreendendo pelo menos três anfipatos, para transporte melhorado através de barreiras semipermeáveis e para aplicação de droga não-invasiva in vivo, especialmente através da pele
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
MXPA06000805A (es) * 2003-07-21 2006-04-18 Vasogen Ireland Ltd Liposomas que contienen grupos de glicerol fosfato para tratar una condicion inflamatoria aguda.
JP2005179313A (ja) * 2003-12-24 2005-07-07 Shu Uemura:Kk 皮膚化粧料用基剤の製造方法および皮膚化粧料
US7476432B2 (en) 2004-05-28 2009-01-13 Tecton Products Phosphorescent pultrusion
JP2008519784A (ja) 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
WO2006086992A2 (en) 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
US20070042008A1 (en) * 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
CA2621066C (en) * 2005-08-29 2011-11-29 Sepsicure L.L.C. Method for treatment or prevention of conditions caused by gram-positive bacteria
NZ569068A (en) * 2005-12-20 2011-11-25 Cenestra Llc Omega 3 fatty acid formulations of EPA and DHA
JP5009547B2 (ja) * 2006-03-31 2012-08-22 株式会社コーセー 顔料とリポソームを含む化粧料
US7544375B1 (en) 2006-06-12 2009-06-09 Swiss Skin Repair, Inc. Composition
CN101541308B (zh) 2006-09-28 2012-02-01 哈达斯特医疗研究服务和开发有限公司 甘油磷脂用于关节润滑的用途
JP4732307B2 (ja) * 2006-11-20 2011-07-27 株式会社アンズコーポレーション ナノエマルション及びそれを配合した化粧料
US20100130611A1 (en) * 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
ITVR20080006A1 (it) 2008-01-23 2009-07-24 David Ceretta Apparato per la realizzazione di elementi d'impasto
ES2335636B1 (es) 2008-02-29 2011-05-11 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica de micelas mixtas.
JP2009256331A (ja) * 2008-03-25 2009-11-05 Nagase Chemtex Corp 高尿酸血症、又は痛風の予防、改善、又は治療剤
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
US20100197621A1 (en) * 2009-02-05 2010-08-05 William Henry Methods of reducing the proliferation and viability of microbial agents
KR20140021950A (ko) * 2009-06-03 2014-02-21 존 찰스 마요 심부 조직 통증 치료 제형
BR112012003834A2 (pt) 2009-08-21 2017-08-08 Targeted Delivery Tech Limited métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote
EP2382994A1 (en) 2010-04-26 2011-11-02 Maurizio Victor Cattaneo Ligand targeted nanocapsules for the delivery of RNAi and other agents
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
US20120045405A1 (en) 2010-08-18 2012-02-23 Gilman Miles E Under eye cream
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201206486D0 (en) 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208409D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
US20160193147A1 (en) 2013-07-31 2016-07-07 Sequessome Technology Holdings Limited Vesicles

Also Published As

Publication number Publication date
JP2013502436A (ja) 2013-01-24
US9452179B2 (en) 2016-09-27
SG178502A1 (en) 2012-03-29
IL218231A0 (en) 2012-04-30
EP2467170A4 (en) 2013-05-29
MX2012002205A (es) 2012-08-03
MX336482B (es) 2016-01-21
CA2774891A1 (en) 2011-02-24
CN102770162A (zh) 2012-11-07
CO6511256A2 (es) 2012-08-31
GB2486371A (en) 2012-06-13
AU2010283998B2 (en) 2015-01-29
GB201204991D0 (en) 2012-05-02
CL2012000446A1 (es) 2012-10-19
DE112010003355T5 (de) 2012-07-12
WO2011022707A1 (en) 2011-02-24
EP2467170A1 (en) 2012-06-27
JP2016040277A (ja) 2016-03-24
NZ598906A (en) 2014-08-29
AU2010283998A1 (en) 2012-04-12
US20140100191A1 (en) 2014-04-10
US20120232034A1 (en) 2012-09-13
CN102770162B (zh) 2016-09-28
EA201290108A1 (ru) 2013-04-30
KR20120129864A (ko) 2012-11-28
US20170035788A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
BR112012003834A2 (pt) métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote
BRPI1007740A2 (pt) sistemas e métodos para tratamento de articulação facetaria
BR112012029457A2 (pt) aparelho eletrodoméstico, sistema de aparelho eletrodoméstico e método para operar o mesmo
BR112013007678A2 (pt) método para tratamento de doenças alérgicas
BR112013013884A2 (pt) métodos de processamento contínuo para produtos biológicos
BR112013011483A2 (pt) método e aparelho para tratar resíduos de cozinha e um produto de resíduo de cozinha
BR112013011874A2 (pt) compostos e métodos para tratar dor
BR112012003092A2 (pt) composições e métodos para implantação de tecido adiposo processado e produtos de tecido adiposo processados.
BR112012003365A2 (pt) método e dispositivo para a fabricação de objetos de titânio.
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BR112013015870A2 (pt) método para o tratamento de biomassa e sistema
BR112013019732A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI1016104A2 (pt) produto de leite e processo
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BR112013003133A2 (pt) processo para o tratamento de uma solução aquosa, e, instalação para o tratamento de uma solução aquosa
UY33119A (es) Método de tratamiento de fibrilación atrial
BR112013012485A2 (pt) método de tratamento com inibidor braf
BR112013002791A2 (pt) processo contínuo de secagem de lamas e instalação de secagem de lamas
BR112012016364A2 (pt) "método para fabricar produtos embutidos, embutidos e dispositivo de produção de embutidos"
BR112013016491A2 (pt) método para tratamento de têxtil
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BR112014015551A8 (pt) método para tratar lama e método para desidratação de lama
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BR112013002123A2 (pt) composição ácida adesiva para limpeza de sanitários e/ou desodorização
BRPI1010086A2 (pt) método e produtos para tratamento de doenças

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2475 DE 12-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.